EPS for Lantheus Holdings, Inc. (LNTH) Expected At $0.21

July 13, 2018 - By Darrin Black

Analysts expect Lantheus Holdings, Inc. (NASDAQ:LNTH) to report $0.21 EPS on August, 7.They anticipate $0.21 EPS change or 50.00 % from last quarter’s $0.42 EPS. LNTH’s profit would be $8.04M giving it 17.68 P/E if the $0.21 EPS is correct. After having $0.22 EPS previously, Lantheus Holdings, Inc.’s analysts see -4.55 % EPS growth. The stock decreased 1.66% or $0.25 during the last trading session, reaching $14.85. About 166,676 shares traded. Lantheus Holdings, Inc. (NASDAQ:LNTH) has declined 14.41% since July 13, 2017 and is downtrending. It has underperformed by 26.98% the S&P500.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. The company has market cap of $568.47 million. The Company’s principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used by radiopharmacies to prepare various nuclear imaging agents; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging of cerebral blood flow. It has a 4.56 P/E ratio. The firm also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke.

Another recent and important Lantheus Holdings, Inc. (NASDAQ:LNTH) news was published by Nasdaq.com which published an article titled: “Consolidated Research: 2018 Summary Expectations for Stock Yards, Archrock, Lantheus, Steelcase, Tableau …” on June 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.